You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

1907 Results
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
EPIrubicin,
oxaliplatin,
fluorouracil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
EPIrubicin,
oxaliplatin,
capecitabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2023
Guidelines and Advice
Status: Current
ID: PET 19
Version: n/a
Nov 2018
Guidelines and Advice
Status: Current
ID: PET 17
Jan 2017
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - MSI-H/dMMR Locally Advanced Unresectable or Metastatic Colorectal Cancer
New Drug Funding Program
    Nivolumab plus Ipilimumab - MSI-H/dMMR Locally Advanced Unresectable or Metastatic Colorectal Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
nivolumab,
ipilimumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Dec 2025
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
nivolumab (Unfunded),
ipilimumab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph, Patient Info Sheet
Sep 2025
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
nivolumab (Compassionate),
ipilimumab (Compassionate)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
New Drug Funding Program
    Bendamustine - Relapsed_Refractory - Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
oBINutuzumab,
bendamustine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2024
Guidelines and Advice
Status: Current
ID: 17-3
Version: 2
Oct 2017

Pages